Compare · CDNA vs ELV
CDNA vs ELV
Side-by-side comparison of CareDx Inc. (CDNA) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 80.1x CDNA ($1.13B).
- CDNA has been more active in the news (4 items in the past 4 weeks vs 3 for ELV).
- ELV has more recent analyst coverage (23 ratings vs 18 for CDNA).
- Company
- CareDx Inc.
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $1.13B
- $90.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 4
- 3
- Recent ratings
- 18
- 23
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CDNA
- President and CEO Hanna John Walter Jr sold $116,045 worth of shares (4,835 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.71% to 671,640 units (SEC Form 4)
- SEC Form DEFA14A filed by CareDx Inc.
- CareDx to Participate in Upcoming Investor Conferences
- Director Torres Arthur A sold $214,676 worth of shares (10,570 units at $20.31), decreasing direct ownership by 21% to 38,665 units (SEC Form 4)
- CareDx Announces Dismissal of 2021 Qui Tam Suit
- Secretary and General Counsel Novack Jeffrey Adam sold $55,581 worth of shares (2,688 units at $20.68) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 113,924 units (SEC Form 4)
- Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,873 shares, decreasing direct ownership by 2% to 116,612 units (SEC Form 4) to satisfy withholding obligation
- CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-3ASR filed by CareDx Inc.
- SEC Form 10-Q filed by CareDx Inc.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)